Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Apatinib is an oral tyrosine kinase inhibitor, which selectively targets vascular endothelial growth factor receptor 2 and has the potential to treat many tumors therapeutically. Cyclic arginylglycylaspartic acid (cRGD)- and polyethylene glycol (PEG)-modified liposomes (cRGD-Lipo-PEG) were constructed to act as a targeted delivery system for the delivery of apatinib to the human colonic cancer cell line, HCT116. These cRGD-modified liposomes specifically recognized integrin α v β 3 and exhibited greater uptake efficiency with respect to delivering liposomes into HCT116 cells when compared to nontargeted liposomes (Lipo-PEG), as well as greater death of tumor cells and apoptosis. The mechanism by which cRGD-Lipo-PEG targets cells was elucidated further with competition assays. To determine the anticancer efficacy in vivo, nude mice were implanted with HCT116 xenografts and treated with apatinib-loaded liposomes or free apatinib intravenously or via intragastric administration. The active and passive targeting of cRGD-Lipo-PEG led to significant tumor treatment targeting ability, better inhibition of tumor growth, and less toxicity when compared with treatments using uncombined apatinib. The results presented strongly support the case for cRGD-Lipo-PEG representing a targeted delivery system for apatinib in the treatment of colonic cancer. Keywords: integrin α v β 3 , cRGD, targeted oral therapy, apatinib, colorectal cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 1×
“Among these, liposomes have been studied extensively in clinical trials as potential carriers of chemotherapeutic agents with decreased side effects and enhanced efficacy in treating cancer.(14) Many liposomal products (amphotericin B: eg, Abelcet, Amphotec, and AmBisome; doxorubicin: eg, Doxil and Caelyx; and daunoru…”
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Mi, Y.-J., Liang, Y.-J., Huang, H.-B., Zhao, H.-Y., Wu, C.-P., Wang, F., Tao, L.-Y., Zhang, C.-Z., Dai, C.-L., Tiwari, A. K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0111 · Cited by 337
Cited by
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Hossain, M. S., Karuniawati, H., Jairoun, A. A., Urbi, Z., Ooi, D. J., John, A., Lim, Y. C., Kibria, K. M. K., Mohiuddin, A. K. M., Ming, L. C., et al. (2022) · Cancers · doi:10.3390/cancers14071732 · Cited by 920
Adapting liposomes for oral drug delivery
He, H., Lu, Y., Qi, J., Zhu, Q., Chen, Z., & Wu, W. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.06.005 · Cited by 663
Self-citationvan der Koog, L., Gandek, T. B., & Nagelkerke, A. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202100639 · Cited by 418
Zhao, S., Ren, S., Jiang, T., Zhu, B., Li, X., Zhao, C., Jia, Y., Shi, J., Zhang, L., Liu, X., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0640 · Cited by 320
Metadata
- Authors
- Song, Z., Lin, Y., Zhang, X., Feng, C., Lu, Y., Gao, Y., & Dong, C.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2017-03
- Volume
- Volume 12
- Pages
- 1941-1958
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2593697091
- Cited by
- 108
- References
- 3
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.